Mobit Paul, Yang Claus Chunli, Nittala Mary R, He Rui, Ahmed Hiba Z, Shultz Gary, Lin Albert, Vijayakumar Srinivasan
Radiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Radiation Oncology, G.V. (Sonny) Montgomery VA Medical Center, Jackson, USA.
Cureus. 2024 Feb 20;16(2):e54572. doi: 10.7759/cureus.54572. eCollection 2024 Feb.
Our institute established an eye plaque interstitial brachytherapy (EPIBT) program in 2007 using the Collaborative Ocular Melanoma Study (COMS) eye plaque. In this case report, we demonstrated an eye plaque treatment planned and executed using Eye Physics Plaque (Los Alamitos, CA) for a 72-year-old male patient with an extra-large tumor with a maximum width of 18.6 mm and height of 13.7 mm. The use of a customized eye plaque, manufactured through three-dimensional (3D) printing, has empowered us to plan and administer treatment for this patient with uveal melanoma. Without this option, enucleation, an option declined by the patient, or proton beam therapy (PBT), which the patient was unwilling to pursue in another state, would have been the alternative course of action. We were able to use more than one activity of the I-125 seeds, which enabled us to shape and reduce the dose to normal surrounding structures at risk within the orbit and in the vicinity of the orbital cavity. Using the dose evaluation tools available with the modern treatment planning system, we reduced the prescription dose from 85 to 70 Gy, with D90 of 140 Gy, thereby providing effective treatment and limiting risk organ doses. In summary, we were able to dose-deescalate without compromising the chances of controlling retinal/scleral tumors. The patient is doing well from a recent follow-up visit 12 months after the eye plaque brachytherapy treatment. The tumor was 4.80 mm high, 1/3 of the original height, and vision is back to 20/60, demonstrating a successful treatment.
我们的研究所于2007年使用协作性眼黑色素瘤研究(COMS)眼敷贴建立了眼敷贴间质近距离放射治疗(EPIBT)项目。在本病例报告中,我们展示了为一名72岁男性患者使用Eye Physics敷贴(加利福尼亚州洛斯阿拉米托斯)进行的眼敷贴治疗计划及实施过程,该患者患有一个超大肿瘤,最大宽度为18.6毫米,高度为13.7毫米。使用通过三维(3D)打印制造的定制眼敷贴,使我们有能力为该葡萄膜黑色素瘤患者制定并实施治疗方案。若没有这个选择,眼球摘除术(患者拒绝的一种选择)或质子束治疗(PBT,患者不愿在另一个州接受这种治疗)将是替代治疗方案。我们能够使用不止一种I-125种子源的活度,这使我们能够塑造并降低眼眶内及眼眶腔附近有风险的正常周围结构的剂量。使用现代治疗计划系统提供的剂量评估工具,我们将处方剂量从85 Gy降至70 Gy,D90为140 Gy,从而在有效治疗的同时限制了危及器官的剂量。总之,我们能够在不影响控制视网膜/巩膜肿瘤几率的情况下降低剂量。在眼敷贴近距离放射治疗后的12个月最近一次随访中,患者情况良好。肿瘤高度为4.80毫米,是原来高度的1/3,视力恢复到20/60,表明治疗成功。